{"id":"mirabegron-tablet","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Hypertension"},{"rate":"2-3%","effect":"Headache"},{"rate":"2-3%","effect":"Nasopharyngitis"},{"rate":"1-2%","effect":"Dizziness"},{"rate":"1-2%","effect":"Tachycardia"},{"rate":"1-2%","effect":"Urinary tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mirabegron activates beta-3 adrenergic receptors on the smooth muscle of the bladder detrusor, causing relaxation and increased bladder capacity during the storage phase of the micturition cycle. Unlike anticholinergic agents, it does not block muscarinic receptors, providing an alternative mechanism for treating overactive bladder symptoms. This sympathomimetic approach allows increased urine storage without the anticholinergic side effects associated with traditional overactive bladder medications.","oneSentence":"Mirabegron is a beta-3 adrenergic receptor agonist that relaxes the detrusor muscle in the bladder to increase urine storage capacity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:23.794Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency"}]},"trialDetails":[{"nctId":"NCT03049462","phase":"PHASE1","title":"The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-03-13","conditions":"Polycystic Ovary Syndrome","enrollment":100},{"nctId":"NCT07310797","phase":"PHASE4","title":"Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion","status":"NOT_YET_RECRUITING","sponsor":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","startDate":"2026-01-01","conditions":"Ureteral Calculi","enrollment":500},{"nctId":"NCT04823442","phase":"NA","title":"Activation of Brown Adipose Tissue Metabolism Using Mirabegron","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2021-01-21","conditions":"Type 2 Diabetes","enrollment":9},{"nctId":"NCT02216214","phase":"PHASE4","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-10-07","conditions":"Overactive Bladder (OAB)","enrollment":888},{"nctId":"NCT01638000","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2012-06-12","conditions":"Urologic Diseases, Urinary Bladder, Overactive, Urinary Bladder Diseases","enrollment":1887},{"nctId":"NCT00912964","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-04-28","conditions":"Urinary Bladder, Overactive","enrollment":2030},{"nctId":"NCT00662909","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-03-28","conditions":"Urinary Bladder, Overactive","enrollment":2149},{"nctId":"NCT00688688","phase":"PHASE3","title":"Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-04-25","conditions":"Urinary Bladder, Overactive","enrollment":2792},{"nctId":"NCT00689104","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-04-28","conditions":"Urinary Bladder, Overactive","enrollment":2336},{"nctId":"NCT04562090","phase":"PHASE4","title":"A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2021-01-06","conditions":"Urge Incontinence, Overactive Bladder (OAB)","enrollment":249},{"nctId":"NCT04641975","phase":"PHASE3","title":"A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-03-15","conditions":"Overactive Bladder (OAB), Pharmacokinetics of Mirabegron","enrollment":26},{"nctId":"NCT02656173","phase":"PHASE4","title":"A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-01-25","conditions":"Overactive Bladder","enrollment":568},{"nctId":"NCT02751931","phase":"PHASE3","title":"Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2016-06-17","conditions":"Neurogenic Detrusor Overactivity","enrollment":91},{"nctId":"NCT04501640","phase":"PHASE4","title":"A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2020-09-21","conditions":"Pharmacokinetics of Mirabegron, Food Effect, Healthy Chinese Subjects","enrollment":24},{"nctId":"NCT02757768","phase":"PHASE4","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-06-13","conditions":"Benign Prostatic Hyperplasia, Overactive Bladder","enrollment":715},{"nctId":"NCT02294396","phase":"PHASE4","title":"Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-10-28","conditions":"Overactive Bladder (OAB)","enrollment":649},{"nctId":"NCT01972841","phase":"PHASE3","title":"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-11-05","conditions":"Urinary Bladder Overactive, Urinary Bladder Diseases\\Urologic Diseases, Overactive Bladder","enrollment":3527},{"nctId":"NCT01908829","phase":"PHASE3","title":"A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2013-07-10","conditions":"Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases","enrollment":2174},{"nctId":"NCT01340027","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2011-03-29","conditions":"Urologic Diseases, Urinary Bladder Diseases, Urological Manifestations","enrollment":1307},{"nctId":"NCT02211846","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-09-21","conditions":"Neurogenic Detrusor Overactivity, Overactive Bladder, Pharmacokinetics of Mirabegron","enrollment":34},{"nctId":"NCT00940121","phase":"PHASE1","title":"Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-04-30","conditions":"Healthy, Pharmacokinetics of Mirabegron","enrollment":91},{"nctId":"NCT06011265","phase":"EARLY_PHASE1","title":"Does Mirabegron Increase the Body Heat Generated by the Nervous System","status":"COMPLETED","sponsor":"Christopher Bell","startDate":"2023-04-27","conditions":"Thermoregulation","enrollment":19},{"nctId":"NCT03817931","phase":"PHASE4","title":"Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2019-08-05","conditions":"Overactive Bladder, Dementia, Lower Urinary Tract Symptoms","enrollment":12},{"nctId":"NCT06123364","phase":"NA","title":"Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Serdinsek Tamara","startDate":"2019-10-14","conditions":"Overactive Bladder, Overactive Bladder Syndrome","enrollment":56},{"nctId":"NCT02086188","phase":"PHASE4","title":"Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis","status":"COMPLETED","sponsor":"Theodore R. Brown, MD MPH","startDate":"2014-05","conditions":"Multiple Sclerosis","enrollment":28},{"nctId":"NCT05617664","phase":"NA","title":"Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis","status":"UNKNOWN","sponsor":"Benha University","startDate":"2022-11-23","conditions":"Nocturnal Enuresis","enrollment":150},{"nctId":"NCT05040984","phase":"","title":"Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2021-04-30","conditions":"Overactive Bladder Syndrome","enrollment":500},{"nctId":"NCT05767632","phase":"PHASE1","title":"Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2022-05-30","conditions":"Healthy","enrollment":30},{"nctId":"NCT02095665","phase":"PHASE4","title":"Ureteral Stent-related Pain and Mirabegron (SPAM) Trial","status":"COMPLETED","sponsor":"Nova Scotia Health Authority","startDate":"2014-01-01","conditions":"Nephrolithiasis","enrollment":22},{"nctId":"NCT04420533","phase":"NA","title":"Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2020-06-05","conditions":"Urinary Bladder, Overactive, Sexual Behavior, Sexual Activity","enrollment":150},{"nctId":"NCT05490082","phase":"PHASE3","title":"Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2022-03-01","conditions":"Voiding Disorders","enrollment":100},{"nctId":"NCT04325880","phase":"PHASE3","title":"Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2021-12-01","conditions":"Ureteral Stent, Stent Related Symptoms","enrollment":240},{"nctId":"NCT02092181","phase":"PHASE4","title":"A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)","status":"COMPLETED","sponsor":"Daniel Burdick, MD","startDate":"2014-03","conditions":"Parkinsons Disease","enrollment":30},{"nctId":"NCT03411252","phase":"EARLY_PHASE1","title":"Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study","status":"TERMINATED","sponsor":"Thomas Jefferson University","startDate":"2018-02-15","conditions":"Achalasia","enrollment":5},{"nctId":"NCT02916693","phase":"PHASE1, PHASE2","title":"Mirabegron For Erectile Dysfunction","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-08-01","conditions":"Erectile Dysfunction, Overactive Bladder, Urinary Incontinence","enrollment":20},{"nctId":"NCT04485585","phase":"PHASE1","title":"A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2020-07-20","conditions":"Benign Prostatic Hyperplasia (BPH), Overactive Bladder","enrollment":36},{"nctId":"NCT04476966","phase":"PHASE1","title":"Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2020-01-20","conditions":"Healthy","enrollment":29},{"nctId":"NCT02138747","phase":"PHASE4","title":"A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-07-24","conditions":"Overactive Bladder (OAB)","enrollment":376},{"nctId":"NCT04286152","phase":"PHASE3","title":"Mirabegron And Ureteral Stent-related Pain (MAP) Trial","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2020-02-03","conditions":"Nephrolithiasis","enrollment":142},{"nctId":"NCT03187795","phase":"PHASE2","title":"Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury","status":"UNKNOWN","sponsor":"Kessler Foundation","startDate":"2019-04-03","conditions":"Spinal Cord Injuries, Urinary Bladder, Neurogenic","enrollment":62},{"nctId":"NCT02787083","phase":"PHASE3","title":"A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis","status":"TERMINATED","sponsor":"Philadelphia Urosurgical Associates","startDate":"2016-08","conditions":"Cystitis, Interstitial","enrollment":9},{"nctId":"NCT02436889","phase":"PHASE4","title":"Treatment of Incontinence Without Memory Problems","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-02","conditions":"Urge Incontinence, Urinary Incontinence, Urge","enrollment":23},{"nctId":"NCT02468375","phase":"PHASE4","title":"Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2015-06","conditions":"Overactive Bladder","enrollment":434},{"nctId":"NCT01898624","phase":"","title":"Specified Drug Use-results Survey of Betanis Tablets","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-12-04","conditions":"Overactive Bladder","enrollment":300},{"nctId":"NCT01901120","phase":"","title":"Long-Term Specified Drug Use-results Survey of Betanis Tablets","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-10","conditions":"Overactive Bladder","enrollment":1263},{"nctId":"NCT02570035","phase":"","title":"Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-12","conditions":"Overactive Bladder, Cardiovascular Disease","enrollment":316},{"nctId":"NCT01919047","phase":"","title":"Drug Use-Results Survey of Betanis Tablets in Japan","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-04","conditions":"Overactive Bladder","enrollment":10711},{"nctId":"NCT00410514","phase":"PHASE2","title":"A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-12","conditions":"Lower Urinary Tract Symptoms, Bladder Outlet Obstruction","enrollment":200},{"nctId":"NCT02010944","phase":"PHASE1","title":"A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-09","conditions":"Phase 1, Bioavailability, Healthy Subjects","enrollment":72},{"nctId":"NCT01964183","phase":"PHASE4","title":"Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-06","conditions":"Pharmacokinetics of Mirabegron and Tolterodine, Healthy","enrollment":24},{"nctId":"NCT01646294","phase":"PHASE1","title":"A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2005-01","conditions":"Pharmacokinetics of YM178, Healthy Subjects","enrollment":34},{"nctId":"NCT01478529","phase":"PHASE1","title":"A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-02","conditions":"Pharmacokinetics of Mirabegron, Bioavailability, Healthy Subjects","enrollment":12},{"nctId":"NCT00939757","phase":"PHASE1","title":"Study of the Effect of Food on the Pharmacokinetics of Mirabegron","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Healthy, Pharmacokinetics of Mirabegron","enrollment":76},{"nctId":"NCT01720212","phase":"PHASE1","title":"Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2012-05","conditions":"Healthy Chinese Volunteers","enrollment":24}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ADVERSE DRUG REACTION"},{"count":1,"reaction":"APHASIA"},{"count":1,"reaction":"CEREBROVASCULAR ACCIDENT"},{"count":1,"reaction":"CONCUSSION"},{"count":1,"reaction":"CONSTIPATION"},{"count":1,"reaction":"DEPRESSION"},{"count":1,"reaction":"DIABETES MELLITUS INADEQUATE CONTROL"},{"count":1,"reaction":"EXPOSURE TO TOXIC AGENT"},{"count":1,"reaction":"FAECALOMA"},{"count":1,"reaction":"FALL"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["YM178"],"phase":"marketed","status":"active","brandName":"Mirabegron tablet","genericName":"Mirabegron tablet","companyName":"Astellas Pharma Inc","companyId":"astellas-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mirabegron is a beta-3 adrenergic receptor agonist that relaxes the detrusor muscle in the bladder to increase urine storage capacity. Used for Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}